DIVI's LABORATORIES LIMITED: HISTORY, LATEST UPDATES, MILESTONES, SUBSIDIARIES & SHARE PRICE
INTRODUCTION
Divi's, established over 30 years ago in Hyderabad, India, with two manufacturing units, ranks among the top pharmaceutical companies in India. Renowned as a reliable supplier of generic APIs and a trusted custom manufacturer for Big Pharma, Divi's holds a prominent position among global API manufacturers. With a focus on producing high-quality APIs, Intermediates, and Registered starting materials, it serves over 100 countries. Recently achieving a milestone as one of the top 3 global API manufacturers and a key player in Hyderabad, Divi's employs approximately 16,500 highly trained professionals, including 400 scientists. As a publicly listed company on the Indian stock exchange, it reported a revenue of around $1.2 billion for the year 2021-22. Divi's advanced manufacturing facilities in Hyderabad and Vizag undergo frequent inspections by various health authorities, including USFDA, EU GMP, HEALTH CANADA, TGA, ANVISA, COFEPRIS, PMDA, and MFDS.
Divi’s LABORATORIES LIMITED MOVES IN 2024
February 2024: The company has reported a 17% increase in year-on-year net profit for Q3FY2024 of Rs. 358 crores. Also, the revenue increased by 8.6% on a year-on-year basis to Rs.1855 crore.
33rd Annual report 2022 – 23, Divi's Labs marked a significant milestone with the groundbreaking ceremony for a new Greenfield Manufacturing Unit (Unit III). The company invested in cutting-edge technologies, expanded production capacities, diversified its Generic API portfolio, introduced new Contrast Media API products, commenced commercial manufacturing, and initiated patent filings for innovative synthesis methods.
On 14th August, 2023, In the first quarter of fiscal year 2024, Divi's Labs recorded a consolidated total income of Rs. 1859 crores.
On 26th September,2023, A delegation from the U.S. Food and Drug Administration (USFDA) visited Divi's Choutuppal Manufacturing Facility. The visit encompassed discussions on various subjects, including the evolving nature of the Active Pharmaceutical Ingredient (API) industry, the incorporation of new technologies, sustainable practices in chemistry, advancements in manufacturing standards, and the assurance of API availability.
On 28th October, 2023, in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Divi’s Labs provided the schedule for the earnings conference call pertaining to the quarter and half-year ending September 30, 2023, scheduled for November 06, 2023
On 26th October, 2023, DIVI's LABORATORIES LTD. had conveyed to BSE that the Board of Directors' meeting was slated for 06/11/2023. The agenda included the consideration and approval of standalone and consolidated unaudited financial results for the quarter and half-year ending September 30, 2023.
On 6th November, 2023, In the second quarter of fiscal year 2024, Divi's Labs reported a consolidated income of Rs. 1995 crores.
EVOLUTION OF DIVI’S LABORATORIES LIMITED: FROM PAST TO PRESENT:
|
Year |
Evolution |
|
12 October 1990 |
Divi's Laboratories founded as Divi's Research Centre, initially focusing on developing commercial processes for API and intermediates manufacturing. |
|
1994 |
Divi's Research Centre renamed to Divi's Laboratories Limited, signalling its entry into API and intermediates manufacturing. |
|
1995 |
Establishment of the first manufacturing facility in Choutuppal, Telangana. |
|
2002 |
Commencement of operations at the second manufacturing facility in Chippada near Visakhapatnam. |
|
February 17, 2003 |
Divi's Laboratories goes public with its initial public offering (IPO). |
|
2010 |
Establishment of a research centre in Hyderabad to further enhance research capabilities. |
|
Company Information |
|
|
Name |
DIVI’S Laboratories Limited |
|
Founded year |
12 October 1990 |
|
Founding chairman |
Mr. Murali Krishna Prasad Divi |
|
Headquarters |
Divi Towers, Cyber Hills, Gachibowli, Hyderabad, Telangana, India |
|
Industry |
Pharmaceuticals |
|
Current MD |
Mr. Murali Krishna Prasad Divi |
|
Major subsidiaries |
Divis Laboratories (USA) Inc Divi’s Laboratories Europe AG Divi’s Nutraceuticals |
|
Revenue |
Rs. 9,073 crore (2023) |
|
Geographical Presence |
India |
|
NSE code |
NSE: DIVISLAB NSE NIFTY 50 Constituent |
|
BSE code |
BSE: 532488 |
TIMELINE OF DIVI’S LABORATORIES LIMITED:
|
Year |
Fact |
Description |
|
12 October 1990 |
Founded |
Established as Divi's Research Centre, Divi's Laboratories initially concentrated on formulating commercial processes for manufacturing APIs and intermediates. |
|
1994 |
Renamed |
Divi's Research Centre underwent a name change to become Divi's Laboratories Limited, indicating its foray into the manufacturing of APIs and intermediates. |
|
1995 |
The inaugural manufacturing facility was set up in Choutuppal, Telangana. |
|
|
2002 |
Commencement |
The second manufacturing facility initiated its operations in Chippada, near Visakhapatnam. |
|
February 17, 2003 |
Listing |
Divi's Laboratories entered the public domain by launching its initial public offering (IPO). |
|
2010 |
Established |
A research center was established in Hyderabad to augment research capabilities. |
INSIDE DIVI’S LABORATORIES LIMITED: EXPLORING SUBSIDIARY VENTURES:
DIVI’S Laboratories Limited
Corporate Actions/ Main News:
• In September 2023, Net Sales reached Rs 1,909.00 crore, marking a 2.94% increase from Rs. 1,854.54 crore in September 2022. • The Quarterly Net Profit for September 2023 was Rs. 348.00 crore, reflecting a 29.5% decrease from Rs. 493.60 crore in September 2022. • EBITDA for September 2023 stands at Rs. 565.00 crore, down by 19.41% from Rs. 701.12 crore in September 2022. • Divis Labs' EPS declined to Rs. 13.11 in September 2023 compared to Rs. 18.60 in September 2022. • As of November 06, 2023, Divis Labs shares closed at 3,506.70 (NSE), with a 7.28% return over the last 6 months and -7.27% over the last 12 months.
LIMITED SUBSIDIARIES NSE/BSE: Current Share Prices
|
COMPANY NAME |
SECTOR |
SHARE PRICE LINK |
|
Divi’s Laboratories Limited |
Pharmaceuticals |
ACHIEVEMENTS & MILESTONE:
|
Year |
Achievements |
|
2022 |
Received the EHS Excellence Award from CII South Region. |
|
2021 |
Received the Lifetime Achievement Award from ICON SWM for significant contributions to the circular economy and waste management. Also honoured with the Lifetime Achievement Award by the International Society of Waste Management, Air & Water (ISWMAW). Recognized for Best Corporate Social Responsibility practices by the World CSR Day Congress & Awards. Achieved a "4 Star Rating" for commitment to Environmental, Health, and Safety (EHS) practices, receiving the CII-SR EHS Excellence Award 2020 from the Confederation of Indian Industry (CII). |
|
2020 |
Received the Prashansa Patra (Appreciation Certificate) at the NSCI Safety Awards 2020 from the National Safety Council of India (NSCI). |
|
2019 |
Achieved a 3-star rating at the CII EHS Excellence Awards 2019 by the Confederation of Indian Industry (CII). Recognized as Runners Up in the large category among all global suppliers at the GSK Environmental Sustainability Supplier Awards 2019 by Glaxo Smith Kline (GSK). Named the 2019 HURUN Self-made Philanthropist of the Year by Hurun Report. Acknowledged as the Best Partner for Smart Village Smart Ward by the Andhra Pradesh State Government. |
|
2018 |
Received recognition at the International Conference on Sustainable Waste Management (IconSWM). Also honoured with the May Day award for Best Management. |
|
2015 |
Received the May Day award for Best Management. |
|
2014 |
Achieved a "Special Commendation" as the winner of the Golden Peacock Award for Corporate Social Responsibility. |
|
2013 |
Received the May Day award for Best Management. |
|
2012 |
Honoured with the India Business Leader Award as the "First Generation Entrepreneur of the Year." |
|
2011 |
Acknowledged for outstanding achievements in "Green Belt Development." |
|
2009 |
Certified and awarded for "Best Green Belt Development." Also received the Best Safety Followers Award for the year 2008 and the Suraksha Puraskar for the year 2008. |
|
2008 |
Received the Shreshta Suraksha Puraskar for the year 2006. Also awarded an appreciation certificate for "Best Cleaner Production Practices and Waste Minimization Techniques" on the occasion of the World Environment. Additionally, recognized as a finalist with a certificate. |
|
2007 |
Acknowledged with an appreciation certificate for "Best Cleaner Production Practices and Waste Minimization Techniques." Also, received the ICC award for excellence in the management of Health/Safety/Environment for the year 2005-2006. |
|
2006 |
Received the National Award for Excellence in Water Management along with a certificate for being a water-efficient unit. This recognition extends beyond the fence, highlighting the exemplary water management practices. |
|
2005 |
Received the National Award for Excellence in Water Management in 2005. Also acknowledged with an appreciation certificate for meritorious performance in implementing programs related to "Safe Guarding the Environment and Pollution Control & Plantation Work." Additionally, honoured with the May Day Award for Best Management. |
|
2004 |
Acknowledged for Good Practice in Cleaner Production and Pollution Control. |
|
2003 |
Received the Shreshtha Suraksha Puraskar and an appreciation certificate for meritorious performance in implementing programs related to "Safe Guarding the Environment and Pollution Control." Also, honoured with the Viswakarma Rashtriya Puraskar. |
|
2002 |
Achieved the May Day Award for Best Management. |
|
1999 -2000 |
Received the Best Exporter Award, Trishul Award for Large-Scale Manufacturers, Samman Patra at the Commissionerate level, and recognized for Best Performance in the Large & Medium Scale Sector. |
|
1998-1999 |
Earned the first award for Large-Scale Manufacturers, including Samman Patra at the Zonal level and All India level. |
|
1998-1996 |
Received recognition for the Best Export Effort in Andhra Pradesh, Trading House, Best Technologies Development in Research and Development (R&D), and Best Export of Chemical Products. |
|
Year |
Milestones |
|
2021 |
Commencement of the construction of a manufacturing plant in Kakinada. |
|
2020 |
Commissioning of new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II, along with the successful completion of the 8th USFDA inspection in Unit 2. |
|
2019 |
An additional investment of $250M is allocated for the expansion of production blocks in Unit -I and Unit- II, concurrent with the 7th USFDA inspection in Unit 2 and the 6th USFDA inspection in Unit 1. |
|
2018 |
Achieving a market capitalization of $5B, the company commissioned 10 new production blocks, underwent the 5th USFDA inspection in Unit 1, and successfully expanded its product portfolio to include over 30 products. |
|
2017 |
Divi's Laboratories reaches a significant milestone by employing 11,000 individuals, establishing itself as a major employer in the combined state of Telangana/Andhra Pradesh. Furthermore, the company achieves recognition as one of the top 3 API manufacturers globally and among the leading API companies in Hyderabad. Additionally, Unit 2 undergoes its 6th USFDA Inspection. |
|
2016 |
Divi's Laboratories achieves a remarkable sales revenue exceeding INR 3,700 crores, reflecting an impressive growth rate of 22%. The company also undergoes its inaugural Anvisa (Brazil) inspection, marking a significant development in its operational evaluations. |
|
2015 |
Divi's Laboratories inaugurates a new corporate office in Hyderabad, providing a modern and enhanced workspace. Additionally, the company unveils a state-of-the-art Pilot block equipped with 160 Reactors and a Kilo Lab, showcasing its commitment to innovation and technological advancement. |
|
2014 |
Divi's Laboratories achieves remarkable financial success, surpassing sales revenue of 2500 crores with an impressive growth rate of 18%. The company also reaches a significant milestone by employing 8700 individuals, reflecting its expanding presence and impact. Furthermore, Divi's Laboratories undergoes its inaugural COFEPRIS inspection, demonstrating its commitment to meeting international regulatory standards. |
|
2013 |
Divi's Laboratories achieves notable milestones with the successful completion of the First Slovenian Medicines Agency inspection for Unit-II, emphasizing its dedication to quality and compliance. Additionally, the company is honoured with the "Premier Trading House" certificate by the Ministry of Commerce & Industry, Government of India, recognizing its excellence in trading activities. |
|
2012 |
Initiation of the initial TGA Inspection. Recognition with the CNBC TV 18 India Business Leader Award as the 'First Generation Entrepreneur of the Year.' |
|
2011 |
Initial EU GMP and Japan PMDA Inspection. |
|
2010 |
Inaugurated a New Research Center in Hyderabad. |
|
2008 |
Successfully underwent the first inspection by MFDS (Korea). |
|
2003 |
Divi's Laboratories got listed on the Indian Stock Exchange. |
|
2002 |
Started operations at the new manufacturing facility (Unit 2) near Visakhapatnam. |
|
2000 |
Started operations at the new manufacturing facility (Unit 2) near Visakhapatnam. |
|
1995 |
Established the first manufacturing facility (Unit-1) near Hyderabad. |
|
1990 |
Founding of Divi's Laboratories as Divi's Research Centre (DRC). |
CONCLUSION
Divi's Laboratories faced a more than 29% decline in consolidated net profit for the September quarter, reporting a figure of Rs. 348 crore compared to Rs.493 crore in the corresponding period last year. This downturn was also evident sequentially from the first quarter of FY24 when the net profit was Rs.356 crore. Despite the decline, the company experienced a 3% increase in total income, reaching Rs.1,995 crore. However, total expenses rose to Rs.1,526 crore, an increase of Rs.206 crore. The company reported a forex gain of Rs.11 crore during the second quarter. Despite these challenges, Divi's Laboratories demonstrated resilience in the market, with its shares closing with a gain of 4.65% at Rs.3,505.70 apiece on the BSE.
FREQUENTLY ASKED QUESTIONS:
What is the Divi’s Laboratories Limited Share Price NSE?
You can check Divi's laboratories share price Today on Enrich Money's stock analysis page.
What is Divi's focus in the pharmaceutical industry?
Divi's Laboratories primarily focuses on the development and manufacturing of APIs (Active Pharmaceutical Ingredients) and intermediates.
Where can I find financial and technical information related to Divi’s Laboratories Limited?
You can check Divi Labs Share Price Today on Enrich Money's stock analysis page for all financial, technical, shareholding patterns, corporate action, news , and Divi’s Laboratories Ltd. Share Price information related to Divi’s Labs.
What are some recent financial highlights of Divi's Laboratories?
Recent financial highlights include a decline in consolidated net profit for the September quarter and a 3% increase in total income to Rs.1,995 crores.
What is the current market capitalization of Divi's Laboratories?
Divi's Laboratories reached a market capitalization of $5 billion.
RELATED BLOGS
-
Cipla Limited: History, Latest Updates, Milestones, Subsidiaries & Share Price
-
SBI: History, Latest Updates, Milestones, Subsidiaries & Share Price
-
Tech Mahindra: History, Latest Updates, Milestones, Subsidiaries & Share Price
-
Larsen & Toubro: History, Latest Updates, Milestones, Subsidiaries and Share Price
-
Bharti Airtel: History, Latest Updates, Milestones, Subsidiaries & Share Price
-
Coal India Limited: History, Latest Updates, Milestones, Subsidiaries & Share Price
Disclaimer: This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.
